JP Patent

JP6706255B2 — 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療

Assigned to バイオキュリティー ファーマシューティカルズ インコーポレイテッド · Expires 2020-06-03 · 6y expired

What this patent protects

Patent listed against Tukysa.

Drugs covered by this patent

Patent Metadata

Patent number
JP6706255B2
Jurisdiction
JP
Classification
—
Expires
2020-06-03
Drug substance claim
No
Drug product claim
No
Assignee
バイオキュリティー ファーマシューティカルズ インコーポレイテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.